[시장보고서]망막정맥폐쇄증 치료 시장 규모, 점유율, 동향 분석 보고서 : 최종사용자별, 질환 유형별, 치료법별, 지역별, 부문별 예측(2023-2030년)

망막정맥폐쇄증 치료 시장 규모, 점유율, 동향 분석 보고서 : 최종사용자별, 질환 유형별, 치료법별, 지역별, 부문별 예측(2023-2030년)

Retinal Vein Occlusion Treatment Market Size, Share & Trends Analysis Report By End-user (Retail Pharmacy, Hospital & Clinics), By Disease Type (CRVO, BRVO), By Treatment (Anti-VEGF, Corticosteroid Drugs), By Region, & Segment Forecasts, 2023 - 2030

상품코드 : 1363066

리서치사 : Grand View Research, Inc.

발행일 : 2023년 09월

페이지 정보 : 영문 180 Pages

라이선스 & 가격 (부가세 별도)

US $ 5,950

￦ 8,443,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950

￦ 9,862,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950

￦ 12,700,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

망막정맥폐쇄증 치료 시장 성장 및 동향:

Grand View Research, Inc.의 최신 보고서에 따르면, 전 세계 망막정맥폐쇄증 치료 시장 규모는 2030년까지 41억 8,000만 달러에 달하고, 2023년부터 2030년까지 6.92%의 CAGR로 성장할 것으로 예상됩니다.

안질환 유병률 증가, 노인 인구 증가, 안질환 치료에 대한 인식 증가가 시장 성장을 이끄는 주요 요인입니다. 기존 제품 및 승인된 제품의 존재와 강력한 제품 파이프라인은 시장 성장을 촉진할 것으로 예상되는 요인입니다. 또한, 당뇨병과 죽상 동맥 경화증의 유병률 증가는 RVO의 유병률을 증가시켜 연구 기간 동안 시장에 긍정적인 영향을 미칠 수 있으며, RVO에 대한 신약 승인의 증가는 연구 기간 동안 시장에 유리한 기회를 제공 할 것으로 예상됩니다.

삼성바이오에피스는 황반부종, 신생혈관성 황반변성, 근시성 맥락막 신생혈관, RVO 등 망막질환 치료제로서 최초의 바이오시밀러 의약품인 바이오시밀러 '비오비즈'(라니비주맙-누나)를 개발했으며, 2020년 9월 미국 FDA로부터 상업화 승인을 받았습니다. 승인을 받았습니다. 그러나 약물과 관련된 높은 비용이 약물 처방을 제한하고 시장 성장을 저해할 수 있으며, BMC Ophthalmology 저널에 게재된 2021년 조사에 따르면 라니비주맙으로 중심성 RVO(CRVO) 및 분지형 RVO(BRVO)를 치료하는 데 있어 중국에서는 질적 조정 생존년(QALY)당 약 449.17달러와 454.75달러의 비용이 소요됩니다. 따라서 높은 효능과 안전성을 갖춘 저렴한 약물의 도입은 예측 기간 동안 시장에 새로운 성장 기회를 가져올 것으로 예상됩니다.

또한 당뇨병성 망막증, 백내장, 녹내장, 황반변성 등의 질환이 전 세계적으로 이 질환의 주요 원인으로 꼽힙니다. 노인 인구의 증가로 인해 RVO에 걸린 사람들이 비례적으로 증가하고 있습니다. 또한, 라이프스타일의 변화로 인해 심혈관 질환, 고혈압 등 RVO를 유발하는 다양한 질환의 발생률도 증가하고 있습니다. 랜싯 세계보건위원회(Lancet Global Health Commission)의 세계 눈 건강 보고서에 따르면, 2020년에는 전 세계 5억 1,000만 명이 교정되지 않은 근거리 시력 장애를, 5억 9,600만 명이 교정되지 않은 원거리 시력 장애를 가지고 있는 것으로 추정되고 있습니다. 이처럼 이차 질환의 유병률 증가는 RVO의 유병률을 증가시켜 시장 성장을 뒷받침할 수 있습니다.

망막정맥폐쇄증 치료 시장 보고서 하이라이트

질병 유형별로는 효율적인 치료를 위한 연구개발 활동과 신약 개발에 대한 투자 증가로 인해 2022년 분지 부문이 시장을 주도했습니다.
치료제별로는 항혈관내피성장인자제제(항VEGF제)가 안전성과 1차 선택약물로서의 보편적 수용성으로 인해 2022년 가장 큰 점유율을 차지했습니다.
소매 약국 최종사용자 부문은 의약품의 접근성 향상과 소매 약국을 통한 RVO의 선택 가능성과 같은 요인으로 인해 2022년에 가장 큰 점유율을 차지했습니다.
북미는 2022년 41.2%의 점유율을 차지하며 지역별로 확고한 입지를 구축했습니다. 이는 이 지역의 정부 자금 증가로 인한 광범위한 R&D 활동과 높은 치료법 채택률로 인한 결과입니다.

시장 세분화와 범위
시장 계통 전망
- 상부 시장 전망
- 관련/부수 시장 전망
시장 역학
시장 성장 촉진요인
- 망막 질환 유병률 증가
- 고령자 인구 증가
- 강력한 제품 포트폴리오의 존재
시장 성장 억제요인 분석
- 이 질병에 대한 인식 결여와 과소 진단
- 높은 치료 비용
사업 환경 분석
- SWOT 분석 : 요인별(정치·법률, 경제·기술)
- Porter's Five Forces 분석
- COVID-19 감염증의 영향 분석

제4장 질환별 비지니스 분석

망막정맥폐쇄증 치료 시장 : 병형 변동 분석
망막중심정맥폐쇄증(CRVO)
망막분지정맥폐쇄증(BRVO)

제5장 치료별 비지니스 분석

망막정맥폐쇄증 치료 시장 : 치료 변동 분석
항혈관내피성장인자(항VEGF)
코르티코스테로이드 치료제
기타

제6장 최종사용자별 비지니스 분석

망막정맥폐쇄증 치료 시장 : 최종사용자 변동 분석
병원과 클리닉
소매 약국
기타

제7장 지역별 비지니스 분석

지역별 망막정맥폐쇄증 치료 시장 점유율, 2022년 및 2030년
북미
유럽
아시아태평양
라틴아메리카
중동 및 아프리카

제8장 경쟁 상황

진출 기업 개요
재무 실적
진출 기업

ksm

영문 목차

영문목차

Retinal Vein OcclusionTreatment Market Growth & Trends:

The global retinal vein occlusion treatment market size is expected to reach USD 4.18 billion by 2030, growingat a CAGR of 6.92% from 2023 to 2030, according to a new report by Grand View Research, Inc.. Growing prevalence of eye diseases, increasing geriatric population, coupled with rising awareness about ophthalmic disease treatment are the key factors boosting the market growth. The presence of already existing products or approved products and a strong product pipeline are factors anticipated to fuel the market growth. Furthermore, the increasing prevalence of diabetes and atherosclerosis may increase the prevalence of RVO and positively impact the market during the study period. Rising approval of novel drugs for RVO is expected to offer lucrative opportunities for the market during the study period.

Samsung Bioepis developed the first biosimilar drug Byooviz (ranibizumab-nuna) for the treatment of retinal disorders, such as macular edema, neovascular age-related macular degeneration, myopic choroidal neovascularization, and RVO. In September 2020, the drug was approved by the FDA for commercialization. However, the high cost associated with drugs may limit the prescription of drugs and hinder market growth. According to a 2021 study published in BMC Ophthalmology, the treatment of central RVO(CRVO) and branch RVO (BRVO) with ranibizumab costs approximately USD 449.17 and USD 454.75 per quality-adjusted life year (QALY) in China. Therefore, the introduction of affordable drugs with high efficacy and safety is expected to create new growth opportunities for the market during the projected timeframe.

Moreover, conditions, such as diabetic retinopathy, cataract, glaucoma, and age-related macular degeneration, are major causes of the disorder globally. A rise in the elderly population is creating a proportionate increase in number of people suffering from RVO. In addition, lifestyle changes have also resulted in increased incidence of various diseases causing RVO, such as cardiovascular diseases & hypertension. According to the Lancet Global Health Commission's report on global eye health, it was estimated that in 2020, 510 million people worldwide had uncorrected close vision impairment, and 596 million people worldwide had uncorrected distance vision impairment. Thus, the increasing prevalence of secondary conditions may increase the prevalence of RVO and support market growth.

Retinal Vein Occlusion Treatment Market Report Highlights:

By disease type, the branch segment dominated themarket in 2022 owing to the increasing focus on R&D activities and investments to develop novel drugs for efficient treatment
By treatment, anti-vascular endothelial growth factor (Anti-VEGF) segment held the largest share in 2022 owing to their safety and universal acceptance as the first-line treatment option
The retail pharmacy end-user segment held the largest share in 2022 due to factors, such as improved accessibility of medication and available options for RVO through retail pharmacies
North America established a strong regional position with a 41.2% share in 2022. This is a result of the region's extensive R&D activities due to increased government funding and a high adoption rate of treatments

Chapter 1. Methodology and Scope

1.1. Market Segmentation
- 1.1.1. Market Definitions
1.2. Objectives
- 1.2.1. Objective - 1
- 1.2.2. Objective - 2
- 1.2.3. Objective - 3
1.3. Research Methodology
1.4. Information Procurement
- 1.4.1. Purchased Database
- 1.4.2. Gvr's Internal Database
- 1.4.3. Secondary Sources
- 1.4.4. Primary Research
1.5. Information Or Data Analysis
- 1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
- 1.7.1. Commodity Flow Analysis
1.8. List of Secondary Sources
1.9. List of Abbreviations
1.10. List of Primary Sources

Chapter 2. Executive Summary

2.1. Market Snapshot
2.2. Disease Type and Treatment Snapshot
2.3. End-user Snapshot
2.4. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
- 3.2.1. Parent Market Outlook
- 3.2.2. Related/Ancillary Market Outlook
3.3. Market Dynamics
3.4. Market Drivers
- 3.4.1. Increasing prevalence of retinal diseases
- 3.4.2. Rising geriatric population
- 3.4.3. Presence of strong product portfolio
3.5. Market Restraint Analysis
- 3.5.1. Lack of awareness and underdiagnoses of the disease
- 3.5.2. High cost of the treatment
3.6. Business Environment Analysis
- 3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
- 3.6.2. Porter's Five Forces Analysis
- 3.6.3. COVID-19 Impact Analysis

Chapter 4. Disease Type Business Analysis

4.1. Retinal Vein Occlusion Treatment market: Disease Type Movement Analysis
4.2. Central Retinal Vein Occlusion (CRVO)
- 4.2.1. Central Retinal Vein Occlusion (CRVO) Market, 2018 - 2030 (USD Million)
4.3. Branch Retinal Vein Occlusion (BRVO)
- 4.3.1. Branch Retinal Vein Occlusion (BRVO) Market, 2018 - 2030 (USD Million)

Chapter 5. Treatment Business Analysis

5.1. Retinal Vein Occlusion Treatment Market: Treatment Movement Analysis
5.2. Anti-vascular Endothelial Growth Factor (Anti-VEGF)
- 5.2.1. Anti-vascular Endothelial Growth Factor (Anti-VEGF) Market, 2018 - 2030 (USD Million)
5.3. Corticosteroid Drugs
- 5.3.1. Corticosteroid Drugs Market, 2018 - 2030 (USD Million)
5.4. Others
- 5.4.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. End-user Business Analysis

6.1. Retinal Vein Occlusion Treatment Market: End-user Movement Analysis
6.2. Hospital & Clinics
- 6.2.1. Hospital & Clinics Market, 2018 - 2030 (USD Million)
6.3. Retail Pharmacy
- 6.3.1. Retail Pharmacy Market, 2018 - 2030 (USD Million)
6.4. Others
- 6.4.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Regional Business Analysis

7.1. Retinal Vein Occlusion Treatment Market Share By Region, 2022 & 2030
7.2. North America
- 7.2.1. North America Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
- 7.2.2. U.S.
  - 7.2.2.1. Key Country Dynamics
  - 7.2.2.2. Target Disease Prevalence
  - 7.2.2.3. Competitive Scenario
  - 7.2.2.4. Regulatory Framework
  - 7.2.2.5. Reimbursement Scenario
  - 7.2.2.6. U.S. Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD MILLION)
- 7.2.3. Canada
  - 7.2.3.1. Key Country Dynamics
  - 7.2.3.2. Target Disease Prevalence
  - 7.2.3.3. Competitive Scenario
  - 7.2.3.4. Regulatory Framework
  - 7.2.3.5. Reimbursement Scenario
  - 7.2.3.6. Canada Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
7.3. Europe
- 7.3.1. Europe Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
- 7.3.2. Germany
  - 7.3.2.1. Key Country Dynamics
  - 7.3.2.2. Target Disease Prevalence
  - 7.3.2.3. Competitive Scenario
  - 7.3.2.4. Regulatory Framework
  - 7.3.2.5. Reimbursement Scenario
  - 7.3.2.6. Germany Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
- 7.3.3. UK
  - 7.3.3.1. Key Country Dynamics
  - 7.3.3.2. Target Disease Prevalence
  - 7.3.3.3. Competitive Scenario
  - 7.3.3.4. Regulatory Framework
  - 7.3.3.5. Reimbursement Scenario
  - 7.3.3.6. UK Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
- 7.3.4. France
  - 7.3.4.1. Key Country Dynamics
  - 7.3.4.2. Target Disease Prevalence
  - 7.3.4.3. Competitive Scenario
  - 7.3.4.4. Regulatory Framework
  - 7.3.4.5. Reimbursement Scenario
  - 7.3.4.6. France Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
- 7.3.5. Italy
  - 7.3.5.1. Key Country Dynamics
  - 7.3.5.2. Target Disease Prevalence
  - 7.3.5.3. Competitive Scenario
  - 7.3.5.4. Regulatory Framework
  - 7.3.5.5. Reimbursement Scenario
  - 7.3.5.6. Italy Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
- 7.3.6. Spain
  - 7.3.6.1. Key Country Dynamics
  - 7.3.6.2. Target Disease Prevalence
  - 7.3.6.3. Competitive Scenario
  - 7.3.6.4. Regulatory Framework
  - 7.3.6.5. Reimbursement Scenario
  - 7.3.6.6. Spain Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
- 7.3.7. Denmark
  - 7.3.7.1. Key Country Dynamics
  - 7.3.7.2. Target Disease Prevalence
  - 7.3.7.3. Competitive Scenario
  - 7.3.7.4. Regulatory Framework
  - 7.3.7.5. Reimbursement Scenario
  - 7.3.7.6. Denmark Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
- 7.3.8. Sweden
  - 7.3.8.1. Key Country Dynamics
  - 7.3.8.2. Target Disease Prevalence
  - 7.3.8.3. Competitive Scenario
  - 7.3.8.4. Regulatory Framework
  - 7.3.8.5. Reimbursement Scenario
  - 7.3.8.6. Sweden Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
- 7.3.9. Norway
  - 7.3.9.1. Key Country Dynamics
  - 7.3.9.2. Target Disease Prevalence
  - 7.3.9.3. Competitive Scenario
  - 7.3.9.4. Regulatory Framework
  - 7.3.9.5. Reimbursement Scenario
  - 7.3.9.6. Norway Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
7.4. Asia Pacific
- 7.4.1. Asia Pacific Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
- 7.4.2. Japan
  - 7.4.2.1. Key Country Dynamics
  - 7.4.2.2. Target Disease Prevalence
  - 7.4.2.3. Competitive Scenario
  - 7.4.2.4. Regulatory Framework
  - 7.4.2.5. Reimbursement Scenario
  - 7.4.2.6. Japan Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
- 7.4.3. China
  - 7.4.3.1. Key Country Dynamics
  - 7.4.3.2. Target Disease Prevalence
  - 7.4.3.3. Competitive Scenario
  - 7.4.3.4. Regulatory Framework
  - 7.4.3.5. Reimbursement Scenario
  - 7.4.3.6. China Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
- 7.4.4. India
  - 7.4.4.1. Key Country Dynamics
  - 7.4.4.2. Target Disease Prevalence
  - 7.4.4.3. Competitive Scenario
  - 7.4.4.4. Regulatory Framework
  - 7.4.4.5. Reimbursement Scenario
  - 7.4.4.6. India Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
- 7.4.5. South Korea
  - 7.4.5.1. Key Country Dynamics
  - 7.4.5.2. Target Disease Prevalence
  - 7.4.5.3. Competitive Scenario
  - 7.4.5.4. Regulatory Framework
  - 7.4.5.5. Reimbursement Scenario
  - 7.4.5.6. South Korea Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
- 7.4.6. Australia
  - 7.4.6.1. Key Country Dynamics
  - 7.4.6.2. Target Disease Prevalence
  - 7.4.6.3. Competitive Scenario
  - 7.4.6.4. Regulatory Framework
  - 7.4.6.5. Reimbursement Scenario
  - 7.4.6.6. Australia Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
- 7.4.7. Thailand
  - 7.4.7.1. Key Country Dynamics
  - 7.4.7.2. Target Disease Prevalence
  - 7.4.7.3. Competitive Scenario
  - 7.4.7.4. Regulatory Framework
  - 7.4.7.5. Reimbursement Scenario
  - 7.4.7.6. Thailand Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
7.5. Latin America
- 7.5.1. Latin America Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
- 7.5.2. Brazil
  - 7.5.2.1. Key Country Dynamics
  - 7.5.2.2. Target Disease Prevalence
  - 7.5.2.3. Competitive Scenario
  - 7.5.2.4. Regulatory Framework
  - 7.5.2.5. Reimbursement Scenario
  - 7.5.2.6. Brazil Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
- 7.5.3. Mexico
  - 7.5.3.1. Key Country Dynamics
  - 7.5.3.2. Target Disease Prevalence
  - 7.5.3.3. Competitive Scenario
  - 7.5.3.4. Regulatory Framework
  - 7.5.3.5. Reimbursement Scenario
  - 7.5.3.6. Mexico Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
- 7.5.4. Argentina
  - 7.5.4.1. Key Country Dynamics
  - 7.5.4.2. Target Disease Prevalence
  - 7.5.4.3. Competitive Scenario
  - 7.5.4.4. Regulatory Framework
  - 7.5.4.5. Reimbursement Scenario
  - 7.5.4.6. Argentina Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
7.6. MEA
- 7.6.1. MEA Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
- 7.6.2. South Africa
  - 7.6.2.1. Key Country Dynamics
  - 7.6.2.2. Target Disease Prevalence
  - 7.6.2.3. Competitive Scenario
  - 7.6.2.4. Regulatory Framework
  - 7.6.2.5. Reimbursement Scenario
  - 7.6.2.6. South Africa Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
- 7.6.3. Saudi Arabia
  - 7.6.3.1. Key Country Dynamics
  - 7.6.3.2. Target Disease Prevalence
  - 7.6.3.3. Competitive Scenario
  - 7.6.3.4. Regulatory Framework
  - 7.6.3.5. Reimbursement Scenario
  - 7.6.3.6. Saudi Arabia Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
- 7.6.4. UAE
  - 7.6.4.1. Key Country Dynamics
  - 7.6.4.2. Target Disease Prevalence
  - 7.6.4.3. Competitive Scenario
  - 7.6.4.4. Regulatory Framework
  - 7.6.4.5. Reimbursement Scenario
  - 7.6.4.6. UAE Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
- 7.6.5. Kuwait
  - 7.6.5.1. Key Country Dynamics
  - 7.6.5.2. Target Disease Prevalence
  - 7.6.5.3. Competitive Scenario
  - 7.6.5.4. Regulatory Framework
  - 7.6.5.5. Reimbursement Scenario
  - 7.6.5.6. Kuwait Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

8.1. Participant's overview
8.2. Financial performance
8.3. Participant categorization
- 8.3.1. Market Leaders
- 8.3.2. Retinal Vein Occlusion Treatment market Share Analysis, 2022
- 8.3.3. Company Profiles
  - 8.3.3.1. AbbVie Inc
  - 8.3.3.1.1. Company Overview
  - 8.3.3.1.2. Financial Performance
  - 8.3.3.1.3. Product Benchmarking
  - 8.3.3.1.4. Strategic Initiatives
  - 8.3.3.2. F. Hoffmann-La Roche Ltd
  - 8.3.3.2.1. Company Overview
  - 8.3.3.2.2. Financial Performance
  - 8.3.3.2.3. Product Benchmarking
  - 8.3.3.2.4. Strategic Initiatives
  - 8.3.3.3. Regeneron Pharmaceuticals Inc
  - 8.3.3.3.1. Company Overview
  - 8.3.3.3.2. Financial Performance
  - 8.3.3.3.3. Product Benchmarking
  - 8.3.3.3.4. Strategic Initiatives
  - 8.3.3.4. Taiwan Liposome Company, Ltd
  - 8.3.3.4.1. Company Overview
  - 8.3.3.4.2. Financial Performance
  - 8.3.3.4.3. Product Benchmarking
  - 8.3.3.4.4. Strategic Initiatives
  - 8.3.3.5. Aerie Pharmaceuticals Inc
  - 8.3.3.5.1. Company Overview
  - 8.3.3.5.2. Financial Performance
  - 8.3.3.5.3. Product Benchmarking
  - 8.3.3.5.4. Strategic Initiatives
  - 8.3.3.6. CalciMedica Inc
  - 8.3.3.6.1. Company Overview
  - 8.3.3.6.2. Financial Performance
  - 8.3.3.6.3. Product Benchmarking
  - 8.3.3.6.4. Strategic Initiatives
  - 8.3.3.7. Outlook Therapeutics, Inc
  - 8.3.3.7.1. Company Overview
  - 8.3.3.7.2. Financial Performance
  - 8.3.3.7.3. Product Benchmarking
  - 8.3.3.7.4. Strategic Initiatives
  - 8.3.3.8. Kodiak Sciences Inc
  - 8.3.3.8.1. Company Overview
  - 8.3.3.8.2. Financial Performance
  - 8.3.3.8.3. Product Benchmarking
  - 8.3.3.8.4. Strategic Initiatives
  - 8.3.3.9. Chugai Pharmaceutical Co., Ltd
  - 8.3.3.9.1. Company Overview
  - 8.3.3.9.2. Financial Performance
  - 8.3.3.9.3. Product Benchmarking
  - 8.3.3.9.4. Strategic Initiatives
  - 8.3.3.10. Pfizer Inc
  - 8.3.3.10.1. Company Overview
  - 8.3.3.10.2. Financial Performance
  - 8.3.3.10.3. Product Benchmarking
  - 8.3.3.10.4. Strategic Initiatives
- 8.3.4. Strategy Mapping
  - 8.3.4.1. Expansion
  - 8.3.4.2. Acquisition
  - 8.3.4.3. Collaborations
  - 8.3.4.4. Disease Type/Drug Class Launch
  - 8.3.4.5. Partnerships
  - 8.3.4.6. Others